mgheaderbig
mgheaderbig

Advances in technology have improved healthcare providers' ability to rapidly diagnose patients at the point of care, screen for common conditions, and provide a variety of effective treatment options. Providers need to be aware of what innovations are available - or will become available in the near future. It is the purpose of Medgizmos to educate and inform healthcare providers regarding the latest and greatest technologies.

Slide 2

Latest Reviews

Image is not available
Connected Technology

ScopeAround Wifi Otoscope, new inexpensive digital otoscope!

Image is not available
Medical Devices

HomeSoap UV-C Sanitizer
System!

Image is not available
Software/Applications

EM University educates providers about the new guidelines!

Slide 2

Latest Interviews/Webinars

Image is not available
Interview

Welch Allyn New 2021 Diagnostic Tools

Image is not available
Webinar

Coding 2021 New
Guidelines

Slide 3

Subscribe to receive notifications of our latest posts.

Slide 3

View our Summer 2021 Newsletter

Slide 3

New! Visit Our Podcast Page

Slide 3

New! Visit MDMtool.org

previous arrow
next arrow

Navigation

Home page sections include recent video reviews, a searchable list of all posts (reviews, webinars and interviews), and a list of post pages organized by topic.

Medgizmos

Is the “virtual medical home” of Andrew J. Schuman MD, who has been writing about medical technology and medical practice for over 30 years!

Update

October 12, 2021:  MDMtool.org online!   Exergen Temporal Artery Thermometer  review now online.  Summer 2021 newsletter available for viewing .

FebriDx Interview

Dr. Rob Sambursky, the President and CEO of Lumos Diagnostics is a very patient man.   His brainchild, the FebriDx point of care system, can help providers distinguish between febrile respiratory infections caused by viruses from those caused by bacteria. It is presently in use in Canada, Europe, Pakistan, Singapore,  and Australia, and currently in clinical trials for approval by the Food and Drug Administration for release in the United States. As Dr. Sambursky discusses in the video, the COVID-19 pandemic, has slowed enrollment in the clinical trials.

In the video Dr. Sambursky discusses the development of the FebriDx system, a journey that began, over 10 years ago. He is a ophthalmologist with additional training in infectious disease. He initially developed a product that could rapidly detect pathogens responsible for eye infections.  This then led to an association with other researchers and eventually his interest in developing a rapid assay for Myxovirus resistance protein A (MxA), an interferon-induced dynamin-like GTPase , which is elevated in febrile respiratory infections.  

The FebriDx test takes is completed in just 10 minutes, and is inexpensive (about $15).  A finger is prepped with an alcohol wipe and dried, the lancet built into the device is activated  and applied to the fingertip.  A plastic tube draws up 5 microliters of finger stick blood which is then transferred to the cartridge mechanism. A button is pressed, releasing agents and a few minutes later, the device indicates whether the patient has elevated Myxovirus resistance protein A and/or CRP.   An elevated CRP indicates bacterial respiratory infection, while an elevated Myxovirus resistance protein A with or without CRP indicated viral infection.

Dr. Sambursky discusses a variety of fascinating topics in the interview.  First and foremost, when point of care PCR tests for identifying COVID-19 infected individuals are in short supply the FebriDX test may help identify those patients  who should be prioritized for  testing.  Myxovirus resistance protein A is elevated in non-novel coronavirus infections, and one would expect that it would be elevated in patients infected with the novel coronavirus. Obviously Lumos Diagnostics will need to demonstrate to the satisfaction of the FDA that Myxovirus resistance protein A is elevated in COVID-19 infections.  Once this has been established in a large cohort of patients, the FDA should consider fast tracking its release in the USA.

Pediatricians in the United States are already familiar with the CRP test and its utility in facilitating clinical decisions, but to date there are no Clia’88 waived POC CRP tests available. I can think of many potential scenarios where the FebriDx can be helpful  – the child who is well appearing and has diffuse rales on lung exam, the crying child who has suspiciously red ears, the well appearing child with a mild sore throat who tests positive for strep and may be a carrier.   We will need to wait until the device is available to decide on its usefulness in clinical practice.

Subscribe

Subscribe

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!